지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2020.6
- 수록면
- 57 - 62 (6page)
이용수
초록· 키워드
오류제보하기
Recent data showed that DNA mismatch repair deficiency can be a predictive biomarker for a favorable response of immune checkpoint inhibitors regardless of tumor type due to give rise to high tumor mutational burden (TMB) and microsatellite instability (MSI). Loss-of-function mutations of a specific tumor suppressor gene can also lead to good response to immunotherapy. Herein, we report a case exhibiting good response to pembrolizumab in a jejunal adenocarcinoma patient with low programmed death-ligand 1 (PD-L1) expression. A 67-year-old man underwent surgical resection followed by adjuvant chemotherapy. After 10 months, he was treated with palliative chemotherapy due to hepatic and pulmonary metastases. However, palliative chemotherapy did not have any effect whatsoever. Based on genetic testing results of high TMB and high MSI in the resected primary tumor, pembrolizumab treatment was performed. After the three cycles of treatment, all metastatic lesions shrank remarkably. Considering the mechanism of immune checkpoint inhibitors, this case establishes the importance of genetic markers as TMB and MSI rather than PD-L1 expression by the prediction of their anti-tumor activities.
목차
INTRODUCTION
CASE REPORT
DISCUSSION
REFERENCES
참고문헌 (15)
참고문헌 신청
Zhang MQ / 2006 / Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma : a comparison with colorectal adenocarcinoma / Mod Pathol 19:573~580
Aparicio T / 2014 / Small bowel adenocarcinoma : epidemiology, risk factors, diagnosis and treatment / Dig Liver Dis 46:97~104
Schumacher TN / 2015 / Neoantigens in cancer immunotherapy / Science 348:69~74
Le DT / 2017 / Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade / Science 357:409~413
Kelderman S / 2015 / Mismatch repair-deficient cancers are targets for anti-PD-1 therapy / Cancer Cell 28:11~13
Aparicio T / 2014 / Small bowel adenocarcinoma : epidemiology, risk factors, diagnosis and treatment / Dig Liver Dis 46:97~104
Schumacher TN / 2015 / Neoantigens in cancer immunotherapy / Science 348:69~74
Le DT / 2017 / Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade / Science 357:409~413
Kelderman S / 2015 / Mismatch repair-deficient cancers are targets for anti-PD-1 therapy / Cancer Cell 28:11~13
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
Cancer Research and Treatment
2022 .04
-
Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability‒High Colon Cancer
Cancer Research and Treatment
2022 .10
-
Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing
Cancer Research and Treatment
2021 .10
-
Tumor immune response and immunotherapy in gastric cancer
Journal of Pathology and Translational Medicine
2020 .01
-
Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer
Cancer Research and Treatment
2020 .01
-
Immune landscape and biomarkers for immuno-oncology in colorectal cancers
Journal of Pathology and Translational Medicine
2020 .01
-
What’s new in molecular genetic pathology 2022: immune checkpoint inhibitor biomarkers and select solid tumors
Journal of Pathology and Translational Medicine
2022 .03
-
Clinical implication of adjuvant chemotherapy according to mismatch repair status in patients with intermediate-risk stage II colon cancer: a retrospective study
Journal of Yeungnam Medical Science
2022 .04
-
Sporadic Early Onset Colorectal Cancer in Pakistan: a Case-Control Analysis of Microsatellite Instability
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Clinical Implications of Microsatellite Instability in Early Gastric Cancer
Journal of Gastric Cancer
2019 .01
-
Checkpoint-inhibition in ovarian cancer: rising star or just a dream?
Journal of Gynecologic Oncology
2018 .01
-
Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Tuberculosis and Respiratory Diseases
2018 .01
-
Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non–small cell lung cancer
Journal of Pathology and Translational Medicine
2024 .03
-
Comparison of the Mismatch Repair System between Primary and Metastatic Colorectal Cancers Using Immunohistochemistry
Journal of Pathology and Translational Medicine
2017 .01
-
A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer
Cancer Research and Treatment
2020 .01
-
Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers
Cancer Research and Treatment
2022 .10
-
Microsatellite instability and the effectiveness of adjuvant treatment in pT1N1 gastric cancer: A multi-cohort study
대한임상종양학회 학술대회지
2021 .06
-
전이성 위암의 새로운 치료 요법
대한내과학회지
2018 .01
-
Immune check point inhibitors in BRAF mutated metastatic colorectal cancer: A review
International Journal of Gastrointestinal Intervention
2024 .07
-
Updates to Clinical Information on Anticancer Immunotherapy
한국임상약학회지
2018 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2020-514-000882438